Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH06102622B2 - 肥満の治療 - Google Patents
[go: Go Back, main page]

JPH06102622B2 - 肥満の治療 - Google Patents

肥満の治療

Info

Publication number
JPH06102622B2
JPH06102622B2 JP2500580A JP50058090A JPH06102622B2 JP H06102622 B2 JPH06102622 B2 JP H06102622B2 JP 2500580 A JP2500580 A JP 2500580A JP 50058090 A JP50058090 A JP 50058090A JP H06102622 B2 JPH06102622 B2 JP H06102622B2
Authority
JP
Japan
Prior art keywords
experiment
weeks
group
sibutramine hydrochloride
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2500580A
Other languages
English (en)
Other versions
JPH02503682A (ja
Inventor
リー スケインバウム，モンテ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boots Co PLC
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23060006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH06102622(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co PLC filed Critical Boots Co PLC
Publication of JPH02503682A publication Critical patent/JPH02503682A/ja
Publication of JPH06102622B2 publication Critical patent/JPH06102622B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 本発明は肥満の医療に関する。
本発明は、治療上有効な量のＮ，Ｎ‐ジメチル‐1-〔1-
（4-クロロフエニル）シクロブチル〕‐3-メチルブチル
アミン塩酸塩を、製薬上容認しうる希釈剤あるいは担体
と共に投与する肥満治療法を提供する。
うつ病の治療にＮ，Ｎ‐ジメチル‐1-〔1-（4-クロロフ
エニル）シクロブチル〕‐3-メチルブチルアミン塩酸塩
を使用する方法が英国特許第2098602号明細書に記載さ
れており、またParkinson病の治療におけるＮ，Ｎ‐ジ
メチル‐1-〔1-（4-クロロフエニル）シクロブチル〕‐
3-メチルブチルアミン塩酸塩の使用は発行PCT特許願第W
O 88/06444号明細書に記載されている。この化合物の特
に好ましい形はＮ，Ｎ‐ジメチル‐1-〔1-（4-クロロフ
エニル）シクロブチル〕‐3-メチルブチルアミン塩酸塩
一水和物（シブトラミン塩酸塩）であり、このものは欧
州特許願第230742号明細書に記載されている。
治療活性のある化合物は、公知の医薬品剤形のいずれ
か、例えば固体剤形、例えば錠剤あるいはカプセル、ま
たは液体剤形、例えば経口または非経口投与を企図した
剤形のいずれかで投与できる。化合物の投与量は幾つか
の因子、例えば患者の年令、症状の軽重、および患者の
過去の病歴により左右され、常に、監督医師の信頼でき
る裁量のうちにあるが、一般に投与すべき化合物の投薬
量は、１回かそれ以上に分割して投与するとして0.1か
ら50mg、なるべくは１から30mg/日の範囲内にあると考
えられる。
シブトラミン塩酸塩がヒトの体重減少を起こす能力を下
記の実験により実証した。
実験１ 39人の健常男子ボランテイア被実験者を三つの群に分け
て処置した。15人の被実験者からなる第一群（群１）
に、実験の最初の２週間は2.5mg/日のシブトラミン塩酸
塩を与え、続いて実験の残りの４週間は5mg/日のシブト
ラミン塩酸塩を投与した。15人の被実験者からなる第二
の群（群２）に、実験の最初の２週間は5mg/日のシブト
ラミン塩酸塩を与え、続いて実験の残りの４週間は10mg
/日のシブトラミン塩酸塩を投与した。９人の被実験者
からなる第三の群（群３）にはシブトラミン塩酸塩を含
まない偽薬を与えた。これら被実験者を実験の毎朝シブ
トラミン塩酸塩あるいは偽薬を１回投与で処置した。各
被実験者の体重を処置の開始および６週後に計つた。被
実験者の開始時の体重（kgで表示）および６週間の実験
期間にわたる体重変化（kgで表示）を表１に示す。
実験２ うつ病に罹つていると診断された56人の被実験者を二つ
の群に分けて処置した。26人の被実験者からなる第一の
群（群１）を、実験の最初の２週間は10mg/日のシブト
ラミン塩酸塩で処置し、次に更に４週間の期間20mg/日
のシブトラミン塩酸塩で処置した。第二の群（群２）に
は実験期間中ずつと毎日偽薬（シブトラミン塩酸塩を含
まず）を与えた。これら被実験者を実験の毎朝シブトラ
ミン塩酸塩か偽薬の１回投与で処置した。各被実験者の
体重を実験の開始時および６週間後に計つた。各被実験
者の開始時の体重（kgで表示）および６週間にわたる体
重変化（kgで表示）を第２に示す。
実験３ 19人の健常男子ボランテイアを二つの群に分けて処置し
た。14人の被実験者からなる第一群（群１）を、実験の
最初の２週間は15mg/日のシブトラミン塩酸塩で処置
し、次に更に４週間の期間は30mgのシブトラミン塩酸塩
で処置した。第二の群（群２）には実験期間中ずつと毎
日偽薬（シブトラミン塩酸塩を含まず）を与えた。これ
ら被実験者を実験の毎朝シブトラミン塩酸塩か偽薬の１
回投与で処置した。各被実験者の体重を実験開始時およ
び６週間後に計つた。実験開始時における各被実験者の
体重（kgで表示）および６週間の期間にわたる体重変化
（kgで表示）を表３に示す。
実験１、２、および３に対して上に報告した結果から、
シブトラミン塩酸塩で処置した被実験者は、各実験の６
週間の期間にわたり、偽薬で処置した被実験者と比較し
た場合、有意な体重減少を体験したことが分かる。

Claims (2)

    【特許請求の範囲】
  1. 【請求項１】Ｎ，Ｎ‐ジメチル‐1-〔1-（4-クロロフェ
    ニル）シクロブチル〕‐3-メチルブチルアミン塩酸塩を
    主成分として、製薬上容認しうる希釈剤あるいは担体と
    共に含有してなる肥満治療用医薬品組成物。
  2. 【請求項２】Ｎ，Ｎ‐ジメチル‐1-〔1-（4-クロロフェ
    ニル）シクロブチル〕‐3-メチルブチルアミン塩酸塩一
    水和物を主成分として、製薬上容認しうる希釈剤あるい
    は担体と共に含有してなる肥満治療用医薬品組成物。
JP2500580A 1988-11-29 1989-11-21 肥満の治療 Expired - Lifetime JPH06102622B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27724088A 1988-11-29 1988-11-29
US277,240 1988-11-29
PCT/GB1989/001383 WO1990006110A1 (en) 1988-11-29 1989-11-21 Treatment of obesity

Publications (2)

Publication Number Publication Date
JPH02503682A JPH02503682A (ja) 1990-11-01
JPH06102622B2 true JPH06102622B2 (ja) 1994-12-14

Family

ID=23060006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2500580A Expired - Lifetime JPH06102622B2 (ja) 1988-11-29 1989-11-21 肥満の治療

Country Status (15)

Country Link
US (1) US5436272A (ja)
EP (1) EP0397831B1 (ja)
JP (1) JPH06102622B2 (ja)
KR (1) KR0164435B1 (ja)
AU (1) AU633529B2 (ja)
CA (1) CA2003524C (ja)
DE (2) DE19975039I2 (ja)
DK (1) DK175587B1 (ja)
IE (1) IE61928B1 (ja)
IL (1) IL92406A (ja)
LU (1) LU90866I2 (ja)
NL (1) NL300066I2 (ja)
PH (1) PH26677A (ja)
WO (1) WO1990006110A1 (ja)
ZA (1) ZA899058B (ja)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
CA2138998A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
EP1162964A1 (en) 1999-03-19 2001-12-19 Knoll GmbH Treatment of pulmonary hypertension
WO2000056308A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6376551B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
MXPA01009465A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Perdida de peso despues del embarazo.
MXPA01009404A (es) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Metodo para tratar trastornos de alimentacion.
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
WO2000056309A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
JP2003521469A (ja) * 1999-03-19 2003-07-15 クノール・ゲー・エム・ベー・ハー 睡眠時無呼吸症を治療する方法
PL365463A1 (en) * 1999-03-19 2005-01-10 Knoll Gmbh Treatment of osteoarthritis
AU3895400A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
IL145241A0 (en) * 1999-03-19 2002-06-30 Knoll Gmbh Method of controlling weight gain associated with therapeutic drugs
JP2002539252A (ja) * 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 胆石の治療
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
JP3813152B2 (ja) * 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP2008526836A (ja) 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
WO2008028914A1 (en) 2006-09-07 2008-03-13 Nycomed Gmbh Combination treatment for diabetes mellitus
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR101560844B1 (ko) 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20100311710A1 (en) * 2008-12-06 2010-12-09 Auspex Pharmaceuticals, Inc. Cyclobutanemethanamine inhibitors of monoamine reuptake
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
IL92406A (en) 1995-07-31
DE68909219T2 (de) 1994-01-13
WO1990006110A1 (en) 1990-06-14
KR0164435B1 (ko) 1999-01-15
IE893690L (en) 1990-05-29
KR900701261A (ko) 1990-12-01
IE61928B1 (en) 1994-11-30
US5436272A (en) 1995-07-25
AU633529B2 (en) 1993-02-04
DK177690A (da) 1990-09-13
DE19975039I2 (de) 2000-03-30
CA2003524C (en) 1999-10-19
EP0397831A1 (en) 1990-11-22
LU90866I2 (fr) 2002-02-18
EP0397831B1 (en) 1993-09-15
AU4620789A (en) 1990-06-26
DK175587B1 (da) 2004-12-13
PH26677A (en) 1992-09-15
DE68909219D1 (de) 1993-10-21
JPH02503682A (ja) 1990-11-01
NL300066I1 (nl) 2001-12-01
ZA899058B (en) 1990-08-29
NL300066I2 (nl) 2002-06-03
CA2003524A1 (en) 1990-05-29
HK1006002A1 (en) 1999-02-05
DK177690D0 (da) 1990-07-26

Similar Documents

Publication Publication Date Title
JPH06102622B2 (ja) 肥満の治療
US5977099A (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
US4590213A (en) Anti-anxiety method
US5990175A (en) Prevention of migraine
KR20010015918A (ko) 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
JPS6047246B2 (ja) うつ病治療薬
JPH09504798A (ja) 早発性射精の治療におけるアルフゾシンまたはテラゾシンの使用
EP0171227B1 (en) Use of propiophenone compound
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
JPH03170475A (ja) 抑うつ症治療剤
WO1995022324A1 (en) Treatment of migraine headaches and formulations
JP2021530568A5 (ja)
EP0529898A1 (en) Potentiation of the antitussive effect of dextromethorphan with acetaminophen (paracetamol)
EP3323416B1 (en) Pharmaceutical composition for treating premature ejaculation
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона
EP0637956B1 (en) Use of remacemide for the treatment of parkinson's disease
HK1006002B (en) Treatment of obesity
US5650443A (en) Method of treatment of parkinson's disease
JP2024084670A5 (ja)
JPH07188040A (ja) 鼻炎治療用組成物
US4716177A (en) Tolrestat for inhibition of weight gain
SU1713587A1 (ru) Способ лечени радикулита
REDDY'S FDA Drug Approvals

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071214

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081214

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081214

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091214

Year of fee payment: 15

EXPY Cancellation because of completion of term